ArticlePLOS global public health2025
Mortality disparities among children and adolescents with tuberculosis in Tanzania Mainland from January 2023 to December 2023: A retrospective cohort study.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Every year, over 10 million people worldwide contract tuberculosis (TB). The 2024 World Health Organisation TB global report indicated that 32% of the total deaths were children and adolescents under 15 years old. The scale of TB highlights the urgent need for action to end the global epidemic by 2030. This study aims to evaluate the mortality rate, survival probabilities, and factors associated with mortality among children and adolescents with TB in Tanzania. A retrospective cohort study was conducted from the Tanzania National Tuberculosis and Leprosy Programme data, which included individuals under 15 years old who began TB treatment between 1st January 2023 and 31st December 2023. The last patient's end-of-follow-up time was on 16th June 2024. The primary outcome of interest in our study was death. We calculated overall and covariate-specific TB mortality rates per 1,000 person-months. The Kaplan-Meier curve was employed to estimate survival probabilities. A total of 10,491 children and adolescents receiving TB treatment were included, nearly half of whom, 5,940 (56.62%), were under age 5 years. A total of 177 (1.69%) died, resulting in a crude mortality rate of 2.86 per 1,000 person-months. Furthermore, TB and HIV co-infection individuals had five times the risk of death (aHR = 5.03, 95% CI = 3.40-7.47, p < 0.001) compared to non-HIV infection. Community referrals were associated with a lower risk of mortality (aHR = 0.54, 95% CI = 0.35-0.84, p = 0.006). We observed significantly lower survival probabilities for patients referred from CTC, with rates of 96.8%, 96.0% and 95.8% at 2, 4, and 6 months, respectively, compared to those referred from the community, which showed higher survival probabilities of 99.5%, 99.3% and 99.2% over the same periods. The findings reveal significant differences in TB mortality in relation to age, referral system and co-infection. Integrating TB services with child healthcare programs and strengthening differentiated service delivery models can improve survival rates. Targeted interventions in high-risk areas are essential to reduce TB mortality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.